Linked Life Data

21344955

Source:http://linkedlifedata.com/resource/pubmed/id/21344955

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21344955rdf:typepubmed:Citationlld:pubmed
pubmed-article:21344955lifeskim:mentionsumls-concept:C0019707lld:lifeskim
pubmed-article:21344955lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:21344955lifeskim:mentionsumls-concept:C0022661lld:lifeskim
pubmed-article:21344955lifeskim:mentionsumls-concept:C0033607lld:lifeskim
pubmed-article:21344955lifeskim:mentionsumls-concept:C0231199lld:lifeskim
pubmed-article:21344955lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:21344955lifeskim:mentionsumls-concept:C0442967lld:lifeskim
pubmed-article:21344955pubmed:issue5lld:pubmed
pubmed-article:21344955pubmed:dateCreated2011-4-6lld:pubmed
pubmed-article:21344955pubmed:abstractTextNon-nucleoside reverse transcriptase inhibitors and enfuvirtide are ineffective against HIV-2 replication. These considerations may have particular significance in the formulation of second-line or salvage regimens for HIV-2 infection when resistance or toxicity precludes the use of protease inhibitors (PIs) or specific nucleoside analogues. We describe a case of a treatment-experienced patient with important limitations in therapeutic options dictated by the presence of HIV-2 infection, severe HIV nephropathy (requiring haemodialysis), intolerance to PIs and clinical contraindications to the use of some nucleoside analogues (anaemia, pancreatic toxicity and high cardiovascular risk). A three-drug regimen based on raltegravir, tenofovir disoproxil fumarate and lamivudine was given, with no major toxicity, good immunological response and complete viral suppression. Our case indicates that regimens based on integrase inhibitors could represent an effective alternative in PI-resistant or PI-intolerant patients with HIV-2, and that tenofovir disoproxil fumarate may be used in patients with end-stage renal disease requiring haemodialysis who cannot take other nucleoside analogues because of treatment-limiting adverse effects.lld:pubmed
pubmed-article:21344955pubmed:languageenglld:pubmed
pubmed-article:21344955pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:citationSubsetIMlld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21344955pubmed:statusMEDLINElld:pubmed
pubmed-article:21344955pubmed:issn1173-2563lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:ZazziMaurizio...lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:BaldelliFranc...lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:FloridiaMarco...lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:FrancisciDani...lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:MartinelliLau...lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:WeimerLiliana...lld:pubmed
pubmed-article:21344955pubmed:authorpubmed-author:MasiniGiuliaGlld:pubmed
pubmed-article:21344955pubmed:issnTypePrintlld:pubmed
pubmed-article:21344955pubmed:volume31lld:pubmed
pubmed-article:21344955pubmed:ownerNLMlld:pubmed
pubmed-article:21344955pubmed:authorsCompleteYlld:pubmed
pubmed-article:21344955pubmed:pagination345-9lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:meshHeadingpubmed-meshheading:21344955...lld:pubmed
pubmed-article:21344955pubmed:year2011lld:pubmed
pubmed-article:21344955pubmed:articleTitleHIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?lld:pubmed
pubmed-article:21344955pubmed:affiliationClinic of Infectious Diseases, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy.lld:pubmed
pubmed-article:21344955pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21344955pubmed:publicationTypeCase Reportslld:pubmed